• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

From stroke to neurodegenerative diseases: The multi-target neuroprotective effects of 3-n-butylphthalide and its derivatives
Publication date: Available online 11 August 2018Source: Pharmacological ResearchAuthor(s): Longjian Huang, Shan Wang, Fei Ma, Yong Zhang, Yuchen Peng, Changhong Xing, Yipu Feng, Xiaoliang Wang, Ying PengAbstractDiscovering effective agents to slow or stop neurodegeneration is a challenging task. Over decades, only a few drugs were approved by Food and Drug Administration (FDA) and most ended in failure. The lessons learned have switched the strategy of drug discovery from designing highly selective ligands to a network pharmacology approach. This enables many natural products like butylphthalide (NBP) once again to be reg...
Source: Pharmacological Research - August 11, 2018 Category: Drugs & Pharmacology Source Type: research

Testosterone and Cardiovascular Diseases: Causes or Consequences: The Lesson from the Last 5 Years
AbstractPurpose of the ReviewThe relationship between the age-dependent decline of testosterone (T) and cardiovascular (CV) risk in men is still a matter of intense debate. In particular, over the last 5  years, several scientific reports have shed a new negative light on the association between T treatment (TTh) and forthcoming CV diseases (CVD). Based on this evidence, the US Food and Drug Administration agency has recommended that all T supplementations carry a warning that they may increase the risk of heart attack and stroke. To better clarify the available data on this topic, we scrutinized and summarized, also by u...
Source: Current Sexual Health Reports - November 16, 2017 Category: Sexual Medicine Source Type: research

PCSK9 Inhibitors and Neurocognitive Adverse Events: Exploring the FDA Directive and a Proposal for N -of-1 Trials
Abstract Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors are a novel class of medications that greatly lower low-density lipoprotein cholesterol (LDL-C) by upregulating LDL receptor availability. In early 2014, the US Food and Drug Administration (FDA) directed developers of PCSK9 inhibitors to monitor neurocognitive adverse effects and consider neurocognitive testing in at least a subset of participants in ongoing late-stage trials. Available trial evidence indicates that neurocognitive adverse events may occur more commonly in individuals receiving an antibody to PCSK9, but these events are unco...
Source: Drug Safety - May 20, 2015 Category: Drugs & Pharmacology Source Type: research